Annual Uterine Cancer Symposium

年度子宫癌研讨会

基本信息

批准号：
7491238
负责人：
Karen Hsieh Lu
金额：
$ 0.1万
依托单位：
UNIVERSITY OF TX MD ANDERSON CAN CTR
依托单位国家：
美国
项目类别：
财政年份：
2004
资助国家：
美国
起止时间：
2004-09-01 至 2009-12-31
项目状态：
已结题

项目摘要

Endometrial cancer is the most common gynecologic malignancy in the United States. Funding for endometrial cancer has traditionally lagged behind that for other gynecological tumors, such as cervical cancer and ovarian cancer. Consequently, in the past there has been a lack of a coordinated basic and translational research effort devoted to endometrial cancer. In 2003, a group of basic scientists and physician- scientists from M.D. Anderson Cancer Center applied for and received NCI funding for an Endometrial Cancer SPORE. This group of investigators currently represents the only concentrated group of federally funded endometrial cancer researchers in the United States. For innovative, translational research in endometrial cancer to move forward, it will be necessary to bring together clinical investigators and laboratory scientists from a variety of different institutions across the country. Therefore, we propose to organize an annual Uterine Cancer Symposium with the following goals: 1) provide a meaningful forum to discuss cutting-edge developments in endometrial cancer biology; 2) attract experts in related fields (such as breast cancer and endocrinology) to encourage multi-disciplinary interactions; 3) promote collaborations between basic scientists and clinical investigators for the development of more innovative, high-impact translational research in endometrial cancer; and 4) encourage young, talented post-doctoral fellows, clinical residents/fellows, and faculty at the assistant professor level to enter the field of endometrial cancer research. The proposed Endometrial Cancer Symposium will be held on an annual basis in Houston, Texas. We successfully organized the 1st Uterine Cancer Biology Symposium in Houston in 2002, and we have a program of confirmed speakers for the 2nd Symposium to be held September 27 and 28, 2004. Topics for the annual Uterine Cancer Symposium series include hormonal mechanisms in endometrial cancer, molecular differences between aggressive (Type 2) and non-aggressive (Type 1) endometrial cancer, epidemiology of endometrial cancer, chemoprevention in high risk cohorts, endometrial hyperplasia/biomarkers of risk, mouse and cell culture models of endometrial cancer, and genetic events important in normal uterine development. For each symposium, a mixture of clinical topics and basic science topics will be presented to )romote the development of quality translational research.

子宫内膜癌是美国最常见的妇科恶性肿瘤。资助子宫内膜癌传统上落后于其他妇科肿瘤，例如宫颈癌癌症和卵巢癌。因此，过去缺乏协调的基础和协调机制。致力于子宫内膜癌的转化研究工作。 2003年，一群基础科学家和医生—— M.D. 安德森癌症中心的科学家申请并获得了 NCI 资助的子宫内膜试验癌症孢子。这组调查人员目前代表了唯一集中的联邦调查组资助美国子宫内膜癌研究人员。用于创新、转化研究子宫内膜癌要向前发展，有必要将临床研究人员和来自全国各地不同机构的实验室科学家。因此，我们建议组织一年一度的子宫癌研讨会，其目标如下： 1) 提供一个有意义的论坛讨论子宫内膜癌生物学的前沿发展； 2）吸引相关领域的专家（如乳腺癌和内分泌学）鼓励多学科互动； 3）促进合作基础科学家和临床研究人员之间的合作，以开发更具创新性、高影响力的药物子宫内膜癌的转化研究； 4）鼓励年轻、有才华的博士后研究员、临床住院医师/研究员和助理教授级别的教员进入子宫内膜癌研究领域。拟议的子宫内膜癌研讨会将每年在德克萨斯州休斯顿举行。我们 2002年在休斯敦成功举办了第一届子宫癌生物学研讨会，我们有定于 2004 年 9 月 27 日至 28 日举行的第二次研讨会的已确认发言人计划。年度子宫癌研讨会系列包括子宫内膜癌的激素机制、分子机制侵袭性（2 型）和非侵袭性（1 型）子宫内膜癌之间的差异、流行病学子宫内膜癌、高危人群的化学预防、子宫内膜增生/风险生物标志物、子宫内膜癌的小鼠和细胞培养模型以及正常子宫中重要的遗传事件发展。每次研讨会都会混合临床主题和基础科学主题）促进高质量转化研究的发展。